gemfibrozil has been researched along with Metabolic Syndrome in 13 studies
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of gemfibrozil, niacin and cholestyramine has profound, beneficial effects on the components of metabolic syndrome." | 9.15 | The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study. ( Cater, G; Devendra, GP; Krasuski, RA; Whitney, EJ, 2011) |
| "The combination of gemfibrozil, niacin and cholestyramine has profound, beneficial effects on the components of metabolic syndrome." | 5.15 | The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study. ( Cater, G; Devendra, GP; Krasuski, RA; Whitney, EJ, 2011) |
| " Of all the medications currently available, the fibric acid derivatives have a cholesterol lowering profile that is most likely to be effective in obese children with the high TG/low HDL phenotype and data from a recently published study of gemfibrozil in children with metabolic syndrome are promising." | 4.89 | Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents. ( Jellerson, KD; Kennedy, MJ; Snow, MZ; Zacchetti, ML, 2013) |
| " Recently conducted metabolic and pharmacokinetic drug-drug interaction studies using gemfibrozil or fenofibrate in combination with five commonly used statins demonstrated a widely different drug interaction potential for these two fibrates." | 2.43 | Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. ( Davidson, MH, 2006) |
| "Identification and treatment of the metabolic syndrome is of enormous public health importance because it is associated with a marked elevation in coronary heart disease risk and affects nearly 25% of adults in the United States." | 2.42 | Fibrates for treatment of the metabolic syndrome. ( Maki, KC, 2004) |
| "The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity." | 2.41 | Treatment of dyslipoproteinemia in the metabolic syndrome. ( Fenselau, S; Schrezenmeir, J; Steinmetz, A, 2001) |
| "In Ppara-null mice, MFD treatment increased body weight, adipose tissue, serum TG and impaired glucose tolerance." | 1.48 | PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling. ( Dai, M; Gonzalez, FJ; Hua, H; Huang, J; Lin, H; Liu, A; Liu, L; Wang, F; Xi, Y; Xu, G; Yang, J; Zhao, T, 2018) |
| " Previous results suggest that vascular dysfunction in OZR is associated with chronic reduction in vascular nitric-oxide (NO) bioavailability and chronic inflammation, both frequently associated with hypercholesterolemia." | 1.35 | Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome. ( Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hua, H | 1 |
| Yang, J | 1 |
| Lin, H | 1 |
| Xi, Y | 1 |
| Dai, M | 1 |
| Xu, G | 1 |
| Wang, F | 1 |
| Liu, L | 1 |
| Zhao, T | 1 |
| Huang, J | 1 |
| Gonzalez, FJ | 1 |
| Liu, A | 1 |
| Kennedy, MJ | 1 |
| Jellerson, KD | 1 |
| Snow, MZ | 1 |
| Zacchetti, ML | 1 |
| Goodwill, AG | 1 |
| Frisbee, SJ | 1 |
| Stapleton, PA | 1 |
| James, ME | 1 |
| Frisbee, JC | 1 |
| Krasuski, RA | 1 |
| Devendra, GP | 1 |
| Cater, G | 1 |
| Whitney, EJ | 1 |
| Singhal, J | 1 |
| Nagaprashantha, L | 1 |
| Vatsyayan, R | 1 |
| Awasthi, S | 1 |
| Singhal, SS | 1 |
| Després, JP | 1 |
| Lemieux, I | 1 |
| Pascot, A | 1 |
| Alméras, N | 1 |
| Dumont, M | 1 |
| Nadeau, A | 1 |
| Bergeron, J | 1 |
| Prud'homme, D | 1 |
| Garber, AJ | 1 |
| Boden, WE | 1 |
| Maki, KC | 1 |
| März, W | 1 |
| Davidson, MH | 1 |
| Steinmetz, A | 1 |
| Fenselau, S | 1 |
| Schrezenmeir, J | 1 |
7 reviews available for gemfibrozil and Metabolic Syndrome
| Article | Year |
|---|---|
Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents.
Topics: Adolescent; Cardiovascular Diseases; Child; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Fibri | 2013 |
Cardiovascular complications of diabetes: prevention and management.
Topics: Blood Pressure; Diabetic Angiopathies; Disease Progression; Gemfibrozil; Humans; Hydroxymethylglutar | 2003 |
Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Thera | 2003 |
Fibrates for treatment of the metabolic syndrome.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hyp | 2004 |
Role of fibrates in reducing coronary risk: a UK Consensus.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil | 2004 |
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Topics: Area Under Curve; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Dr | 2006 |
Treatment of dyslipoproteinemia in the metabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; | 2001 |
2 trials available for gemfibrozil and Metabolic Syndrome
| Article | Year |
|---|---|
The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study.
Topics: Aged; Anticholesteremic Agents; Body Mass Index; Cholestyramine Resin; Double-Blind Method; Drug The | 2011 |
Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome.
Topics: Adult; Body Constitution; C-Reactive Protein; Coronary Artery Disease; Gemfibrozil; Humans; Hyperlip | 2003 |
4 other studies available for gemfibrozil and Metabolic Syndrome
| Article | Year |
|---|---|
PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Body Weight; Fenofibrate; Fibric Acids; Gemfibrozil; Glucose | 2018 |
Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Arterioles; Atorvastatin; Cytokines; Gemfibrozil; Heptanoic Acids | 2009 |
RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome.
Topics: Animals; Antisense Elements (Genetics); Atorvastatin; Gemfibrozil; GTPase-Activating Proteins; Hepta | 2011 |
[Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mell | 2005 |